Synmosa Biopharma Corp (4114):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Synmosa Biopharma Corp (4114) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8053
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Synmosa Biopharma Corp (Synmosa) is a pharmaceutical company that manufactures, markets and distributes generic medicines. The company produces non-pharmaceutical products such as cosmeceutical and nutrition products, and food supplements in effervescent tablet and granule forms. It offers products in the therapeutic areas of cardiovascular, respiratory, urology, sex hormone, gynecology and cancer treatment. Synmosa also provides contract manufacturing services. The company offers its products in various dosage forms such as nasal sprays, solids, semi-solids and liquids. It markets its products through a distribution network to medical centers, regional hospitals, district hospitals, clinics and drug stores. The company has partners in Finland, France, Japan, Australia, Thailand, Singapore, and others. Synmosa is headquartered in Taipei, Taiwan.

Synmosa Biopharma Corp (4114) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Innopharmax Raises Funds in Venture Financing 10
Licensing Agreements 11
Tibet Hemony Pharma Enters into Licensing Agreement with Synmosa Biopharma 11
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 12
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 13
Equity Offering 14
Innopharmax to Raise up to USD5.2 Million in Public Offering 14
Synmosa Biopharma Raises USD2 Million in Public Offering of Shares 15
Synmosa Biopharma Raises USD15 Million in Rights Offering of Shares 16
Innopharmax Raises USD8 Million in Rights Offering of Shares 17
Innopharmax Completes IPO 18
Acquisition 19
Synmosa Biopharma Plans to Acquire Remaining Stake in Pharmaceutical Company for USD4.2 Million 19
Synmosa and InnoPharmax Acquire Minority Stake in Seven Star Pharma 20
Innopharmax to Acquire 16% Stake in Pharma Company 21
Synmosa Biopharma Acquires Ningbo Youhe Commercial Pharma 22
Synmosa Biopharma To Acquire Majority Stake In Pharma Company 23
Synmosa Biopharma Corp – Key Competitors 24
Synmosa Biopharma Corp – Key Employees 25
Synmosa Biopharma Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synmosa Biopharma Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innopharmax Raises Funds in Venture Financing 10
Tibet Hemony Pharma Enters into Licensing Agreement with Synmosa Biopharma 11
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 12
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 13
Innopharmax to Raise up to USD5.2 Million in Public Offering 14
Synmosa Biopharma Raises USD2 Million in Public Offering of Shares 15
Synmosa Biopharma Raises USD15 Million in Rights Offering of Shares 16
Innopharmax Raises USD8 Million in Rights Offering of Shares 17
Innopharmax Completes IPO 18
Synmosa Biopharma Plans to Acquire Remaining Stake in Pharmaceutical Company for USD4.2 Million 19
Synmosa and InnoPharmax Acquire Minority Stake in Seven Star Pharma 20
Innopharmax to Acquire 16% Stake in Pharma Company 21
Synmosa Biopharma Acquires Ningbo Youhe Commercial Pharma 22
Synmosa Biopharma To Acquire Majority Stake In Pharma Company 23
Synmosa Biopharma Corp, Key Competitors 24
Synmosa Biopharma Corp, Key Employees 25
Synmosa Biopharma Corp, Subsidiaries 26

List of Figures
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synmosa Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Synmosa Biopharma Corp (4114):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cyalume Technologies Holdings, Inc.:企業の戦略・SWOT・財務情報
    Cyalume Technologies Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cyalume Technologies Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Mapletree Investments Pte Ltd:企業の戦略的SWOT分析
    Mapletree Investments Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Tetraphase Pharmaceuticals Inc (TTPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Tetraphase Pharmaceuticals Inc (Tetraphase) is a pharmaceutical company that discovers and develops antibiotic resistance medicines. The company’s products under clinical development include eravacycline, TP-271, and TP-6076. It develops products for the treatment of respiratory diseases cau …
  • Arch Pharmalabs Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Arch Pharmalabs Ltd (Arch Pharmalabs) is a healthcare products company that offers pharmaceutical ingredients. The company manufactures, develops and markets active APIs and intermediates. It offers products such as docetaxel anhydrous and trihydrate, amlodipine besylate, perindopril erbumin …
  • Bacardi Ltd:企業の戦略的SWOT分析
    Bacardi Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Citation Oil & Gas Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Citation Oil & Gas Corp (Citation) is an oil and gas exploration company that acquires, produces, and develops oil and gas properties. The company's products include natural gas, NGL, crude oil, and coalbed methane gas. It conducts asset development program for production and recoverable res …
  • Baxter International Inc.:企業の戦略・SWOT・財務情報
    Baxter International Inc. - Strategy, SWOT and Corporate Finance Report Summary Baxter International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Pioneer Natural Resources Co Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Pioneer Natural Resources Co Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Pioneer Natural Resources Co (Pioneer) is an independent oil and natural gas exploration and production company. Its principally operates in Eagle Ford Shale, Permian Basin, Raton Basin, …
  • Unigroup Inc:企業の戦略・SWOT・財務分析
    Unigroup Inc - Strategy, SWOT and Corporate Finance Report Summary Unigroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • CEZ, AS (CEZ)-エネルギー分野:企業M&A・提携分析
    Summary CEZ, a.s. (CEZ) is an integrated energy conglomerate that extracts and sells coal; generates and distributes electricity and heat; and trades in electricity, natural gas, and other commodities. It generates electricity from nuclear, coal, gas, hydro, solar, wind, and biogas sources. The comp …
  • NeoDynamics AB:製品パイプライン分析
    Summary NeoDynamics AB (NeoDynamics) is an independent medical technology company that focuses on the development of medical solutions for the quick detection and treatment of cancer. It is developing the NeoNavia biopsy system that helps collect samples from breast lesions or axillary lymph nodes f …
  • Bank of Scotland Plc:企業のM&A・事業提携・投資動向
    Bank of Scotland Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Scotland Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Nabriva Therapeutics Plc (NBRV):製薬・医療:M&Aディール及び事業提携情報
    Summary Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company’s product candidate includes lefamulin, a pleuromutilin antibiotic, being developed in both intravenous and oral formulations for the treatm …
  • King Yuan Electronics Co Ltd (2449):企業の財務・戦略的SWOT分析
    King Yuan Electronics Co Ltd (2449) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Curevac AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Curevac AG (Curevac), formerly CureVac GmbH is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its RN …
  • Midshire Catering Services Limited:企業の戦略・SWOT・財務情報
    Midshire Catering Services Limited - Strategy, SWOT and Corporate Finance Report Summary Midshire Catering Services Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Wawa Inc:企業の戦略・SWOT・財務情報
    Wawa Inc - Strategy, SWOT and Corporate Finance Report Summary Wawa Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Indena SpA:企業の戦略的SWOT分析
    Indena SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Fresenius Medical Care AG & Co. KGaA:企業の戦略・SWOT・財務情報
    Fresenius Medical Care AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report Summary Fresenius Medical Care AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • The Boston Beer Company, Inc.:企業の戦略・SWOT・財務情報
    The Boston Beer Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Boston Beer Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆